NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors

References

• Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, Weller M, Stupp R. Current concepts and management of glioblastoma. Ann Neurol 2011; 70:9-21; PMID:21786296; http://dx.doi.org/10.1002/ana.22425
   PubMed Web of Science ®Google Scholar
• Bielamowicz K, Khawja S, Ahmed N. Adoptive cell therapies for glioblastoma. Front Oncol 2013; 3:275; PMID:24273748; http://dx.doi.org/10.3389/fonc.2013.00275
   PubMedGoogle Scholar
• Jung TY, Choi YD, Kim YH, Lee JJ, Kim HS, Kim JS, Kim SK, Jung S, Cho D. Immunological characterization of glioblastoma cells for immunotherapy. Anticancer Res 2013; 33:2525-33; PMID:23749904
   PubMed Web of Science ®Google Scholar
• Ullrich E, Koch J, Cerwenka A, Steinle A. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology 2013; 2:e26097; PMID:24353908; http://dx.doi.org/10.4161/onci.26097
   PubMed Web of Science ®Google Scholar
• Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010; 235:267-85; PMID:20536569; http://dx.doi.org/10.1111/j.0105-2896.2010.00893.x
   PubMed Web of Science ®Google Scholar
• Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Ann Rev Immunol 2013; 31:413-41; PMID:23298206; http://dx.doi.org/10.1146/annurev-immunol-032712-095951
   PubMed Web of Science ®Google Scholar
• Fernandez-Messina L, Ashiru O, Aguera-Gonzalez S, Reyburn HT, Vales-Gomez M. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells. J Cell Sci 2011; 124:321-7; PMID:21224393; http://dx.doi.org/10.1242/jcs.076042
   PubMed Web of Science ®Google Scholar
• Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27:5944-58; PMID:18836475; http://dx.doi.org/10.1038/onc.2008.272
   PubMed Web of Science ®Google Scholar
• Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT. TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. NeuroOncol 2010; 12:7-13; PMID:20150362; http://dx.doi.org/10.1093/neuonc/nop009
   PubMed Web of Science ®Google Scholar
• Leung WH, Vong QP, Lin W, Janke L, Chen T, Leung W. Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXR gamma activation. J Exp Med 2013; 210:2675-92; PMID:24190430; http://dx.doi.org/10.1084/jem.20122292
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG, Steinle A. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008; 68:6368-76; PMID:18676862; http://dx.doi.org/10.1158/0008-5472.CAN-07-6768
   PubMed Web of Science ®Google Scholar
• Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Furst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17. Int J Cancer 2013; 133:1557-66; PMID:23526433; http://dx.doi.org/10.1002/ijc.28174
   PubMed Web of Science ®Google Scholar
• Wolpert F, Tritschler I, Steinle A, Weller M, Eisele G. A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. NeuroOncol 2014; 16:382-91; PMID:24327582; http://dx.doi.org/10.1093/neuonc/not232
   PubMed Web of Science ®Google Scholar
• Chitadze G, Bhat J, Lettau M, Janssen O, Kabelitz D. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol 2013; 78:120-9; PMID:23679194; http://dx.doi.org/10.1111/sji.12072
   PubMed Web of Science ®Google Scholar
• Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. CurrMolPharmacol 2012; 5:102-14; PMID:22122467; http://dx.doi.org/10.2174/1874467211205010102
   PubMedGoogle Scholar
• Lamb LS, Jr, Bowersock J, Dasgupta A, Gillespie GY, Su Y, Johnson A, Spencer HT. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. PloS One 2013; 8:e51805; PMID:23326319; http://dx.doi.org/10.1371/journal.pone.0051805
   PubMed Web of Science ®Google Scholar
• Harly C, Guillaume Y, Nedellec S, Peigne CM, Monkkonen H, Monkkonen J, Li J, Kuball J, Adams EJ, Netzer S et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood 2012; 120:2269-79; PMID:22767497; http://dx.doi.org/10.1182/blood-2012-05-430470
   PubMed Web of Science ®Google Scholar
• Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, El Daker S, Beddoe T, Theodossis A, Williams NK, Gostick E et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nat Immunol 2013; 14:908-16; PMID:23872678; http://dx.doi.org/10.1038/ni.2665
   PubMed Web of Science ®Google Scholar
• Wang H, Henry O, Distefano MD, Wang YC, Räikkönen J, Mönkkönen J, Tanaka Y, Morita CT. Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells. J Immunol 2013; 191:1029-42; PMID:23833237; http://dx.doi.org/10.4049/jimmunol.1300658
   PubMed Web of Science ®Google Scholar
• Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197:163-8; PMID:12538656; http://dx.doi.org/10.1084/jem.20021500
   PubMed Web of Science ®Google Scholar
• Kabelitz D, Wesch D, He W. Perspectives of γδ T cells in tumor immunology. Cancer Res 2007; 67:5-8; PMID:17210676; http://dx.doi.org/10.1158/0008-5472.CAN-06-3069
   PubMed Web of Science ®Google Scholar
• Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, Kabelitz D, Wesch D. Lysis of a broad range of epithelial tumour cells by human γδ T cells: involvement of NKG2D ligands and T-cell receptor- vs. NKG2D-dependent recognition. Scand J Immunol 2007; 66:320-8; PMID:17635809; http://dx.doi.org/10.1111/j.1365-3083.2007.01963.x
   PubMed Web of Science ®Google Scholar
• Bryant NL, Gillespie GY, Lopez RD, Markert JM, Cloud GA, Langford CP, Arnouk H, Su Y, Haines HL, Suarez-Cuervo C et al. Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme. J Neurooncol 2011; 101:179-88; PMID:20532954; http://dx.doi.org/10.1007/s11060-010-0245-2
   PubMed Web of Science ®Google Scholar
• Ashiru O, Boutet P, Fernandez-Messina L, Aguera-Gonzalez S, Skepper JN, Vales-Gomez M, Reyburn HT. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 2010; 70:481-9; PMID:20068167; http://dx.doi.org/10.1158/0008-5472.CAN-09-1688
   PubMed Web of Science ®Google Scholar
• Fernandez-Messina L, Ashiru O, Boutet P, Aguera-Gonzalez S, Skepper JN, Reyburn HT, Vales-Gomez M. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J BiolChem 2010; 285:8543-51; PMID:20080967; http://dx.doi.org/10.1074/jbc.M109.045906
   PubMed Web of Science ®Google Scholar
• Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003; 102:1186-95; PMID:12714508; http://dx.doi.org/10.1182/blood-2002-12-3775
   PubMed Web of Science ®Google Scholar
• Bryant NL, Suarez-Cuervo C, Gillespie GY, Markert JM, Nabors LB, Meleth S, Lopez RD, Lamb LS, Jr. Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastoma. NeuroOncol 2009; 11:357-67; PMID:19211933; http://dx.doi.org/10.1215/15228517-2008-111
   PubMed Web of Science ®Google Scholar
• Espinosa E, Belmant C, Pont F, Luciani B, Poupot R, Romagné F, Brailly H, Bonneville M, Fournié JJ. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human γδ T cells. J BiolChem 2001; 276: 18337-44; PMID:11279081; http://dx.doi.org/10.1074/jbc.M100495200
   PubMed Web of Science ®Google Scholar
• Janssen O, Wesselborg S, Heckl-Östreicher B, Pechhold K, Bender A, Schondelmaier S, Moldenhauer G, Kabelitz D. T cell receptor/CD3-signaling induces death by apoptosis in human T cell receptor γδ+ T cells. J Immunol 1991; 146:35-9; PMID:1824593
   PubMed Web of Science ®Google Scholar
• Stern-Ginossar N, Mandelboim O. An integrated view of the regulation of NKG2D ligands. Immunology 2009; 128:1-6; PMID:19689730; http://dx.doi.org/10.1111/j.1365-2567.2009.03147.x
   PubMed Web of Science ®Google Scholar
• Aguera-Gonzalez S, Boutet P, Reyburn HT, Vales-Gomez M. Brief residence at the plasma membrane of the MHC class I-related chain B is due to clathrin-mediated cholesterol-dependent endocytosis and shedding. J Immunol 2009; 182:4800-8; PMID:19342658; http://dx.doi.org/10.4049/jimmunol.0800713
   PubMed Web of Science ®Google Scholar
• Aguera-Gonzalez S, Gross CC, Fernandez-Messina L, Ashiru O, Esteso G, Hang HC, Reyburn HT, Long EO, Vales-Gomez M. Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding. Eur J Immunol 2011; 41:3667-76; PMID:21928280; http://dx.doi.org/10.1002/eji.201141645
   PubMed Web of Science ®Google Scholar
• Gooz M. ADAM-17: the enzyme that does it all. Crit Rev BiochemMolBiol 2010; 45:146-69; PMID:20184396; http://dx.doi.org/10.3109/10409231003628015
   PubMed Web of Science ®Google Scholar
• Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003; 17:7-30; PMID:12514095; http://dx.doi.org/10.1101/gad.1039703
   PubMed Web of Science ®Google Scholar
• Hedlund M, Nagaeva O, Kargl D, Baranov V, Mincheva-Nilsson L. Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PloS One 2011; 6:e16899; PMID:21364924; http://dx.doi.org/10.1371/journal.pone.0016899
   PubMed Web of Science ®Google Scholar
• Salih HR, Holdenrieder S, Steinle A. Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci 2008; 13:3448-56; PMID:18508446; http://dx.doi.org/10.2741/2939
   PubMed Web of Science ®Google Scholar
• Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med 2012; 10:134; PMID:22738135; http://dx.doi.org/10.1186/1479-5876-10-134
   PubMed Web of Science ®Google Scholar
• Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Nat AcadSci USA 2006; 103:9190-5; PMID:16754847; http://dx.doi.org/10.1073/pnas.0603503103
   PubMed Web of Science ®Google Scholar
• Kato N, Tanaka J, Sugita J, Toubai T, Miura Y, Ibata M, Syono Y, Ota S, Kondo T, Asaka M et al. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 2007; 21:2103-8; PMID:17625602; http://dx.doi.org/10.1038/sj.leu.2404862
   PubMed Web of Science ®Google Scholar
• Huang B, Sikorski R, Sampath P, Thorne SH. Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J Immunother 2011; 34:289-96; PMID:21389869; http://dx.doi.org/10.1097/CJI.0b013e31820e1b0d
   PubMed Web of Science ®Google Scholar
• Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Röcken C. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res ClinOncol 2005; 131:41-8; PMID:15565459; http://dx.doi.org/10.1007/s00432-004-0619-y
   PubMed Web of Science ®Google Scholar
• Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009; 15:1140-4; PMID:19228719; http://dx.doi.org/10.1158/1078-0432.CCR-08-1585
   PubMed Web of Science ®Google Scholar
• Witters L, Scherle P, Friedman S, Fridman J, Caulder E, Newton R, Lipton A. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res 2008; 68:7083-9; PMID:18757423; http://dx.doi.org/10.1158/0008-5472.CAN-08-0739
   PubMed Web of Science ®Google Scholar
• Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J ClinOncol 2002; 20:1383-8; PMID:11870183; http://dx.doi.org/10.1200/JCO.20.5.1383
   PubMed Web of Science ®Google Scholar
• Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 2006; 80:83-90; PMID:16639492; http://dx.doi.org/10.1007/s11060-006-9160-y
   PubMed Web of Science ®Google Scholar
• Rose-John S. ADAM17, shedding, TACE as therapeutic targets. Pharmacol Res 2013; 71:19-22; PMID:23415892; http://dx.doi.org/10.1016/j.phrs.2013.01.012
   PubMed Web of Science ®Google Scholar
• Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, Xu J, Rovis TL, Xiong N, Raulet DH. Antitumor immunity.A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 2015; 348:136-9; PMID:25745066; http://dx.doi.org/10.1126/science.1258867
   PubMed Web of Science ®Google Scholar
• Angelini DF, Zambello R, Galandrini R, Diamantini A, Placido R, Micucci F, Poccia F, Semenzato G, Borsellino G, Santoni A et al. NKG2A inhibits NKG2C effector functions of γδ T cells: implications in health and disease. J LeukocBiol 2011; 89: 75-84; PMID:20952657; http://dx.doi.org/10.1189/jlb.0710413
   PubMed Web of Science ®Google Scholar
• Shojaei H, Oberg HH, Juricke M, Marischen L, Kunz M, Mundhenke C, Gieseler F, Kabelitz D, Wesch D. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human γδ T cells. Cancer Res 2009; 69:8710-7; PMID:19887600; http://dx.doi.org/10.1158/0008-5472.CAN-09-1602
   PubMed Web of Science ®Google Scholar
• Toutirais O, Cabillic F, LeFriec G, Salot S, Loyer P, Le Gallo M, Desille M, de LaPintiere CT, Daniel P, Bouet F et al. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vg9Vd2 T cells. Eur J Immunol 2009; 39:1361-8; PMID:19404979; http://dx.doi.org/10.1002/eji.200838409
   PubMed Web of Science ®Google Scholar
• Fadul CE, Fisher JL, Gui J, Hampton TH, Cote AL, Ernstoff MS. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. NeuroOncol 2011; 13:393-400; PMID:21339188; http://dx.doi.org/10.1093/neuonc/noq204
   PubMed Web of Science ®Google Scholar
• Jin J, Joo KM, Lee SJ, Jo MY, Kim Y, Jin Y, Kim JK, Ahn JM, Yoon MJ, Lim J et al. Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma. Oncol Rep 2011; 25:33-9; PMID:21109954; http://dx.doi.org/10.3892/or_00001038
   PubMed Web of Science ®Google Scholar
• Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C, Salot S, Saiagh S, Audrain M, Rimbert M et al. Phase-I study of Innacellγδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer ImmunolImmunother 2008; 57:1599-609; PMID:18301889; http://dx.doi.org/10.1007/s00262-008-0491-8
   PubMedGoogle Scholar
• Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T, Goto S, Yokokawa K, Suzuki K. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. ExpHematol 2009; 37:956-68; PMID:19409955; http://dx.doi.org/10.1016/j.exphem.2009.04.008
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, Minato N, Toma H. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer ImmunolImmunother 2007; 56:469-76; PMID:16850345; http://dx.doi.org/10.1007/s00262-006-0199-6
   PubMedGoogle Scholar
• Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, Nieda M. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 2011; 105:778-86; PMID:21847128; http://dx.doi.org/10.1038/bjc.2011.293
   PubMed Web of Science ®Google Scholar
• Oberg HH, Peipp M, Kellner C, Sebens S, Krause S, Petrick D, Adam-Klages S, Röcken C, Becker T, Vogel I et al. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells. Cancer Res 2014; 74:1349-60; PMID:24448235; http://dx.doi.org/10.1158/0008-5472.CAN-13-0675
   PubMed Web of Science ®Google Scholar
• Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102:1389-96; PMID:12714493; http://dx.doi.org/10.1182/blood-2003-01-0019
   PubMed Web of Science ®Google Scholar
• Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. ClinDiagnLaboImmunol 2001; 8:1131-5; PMID:11687452; http://dx.doi.org/10.1128/CDLI.8.6.1131–1135.2001
   Web of Science ®Google Scholar